共 50 条
What's new in Hodgkin's lymphoma: ASH 2012 and more
被引:0
|作者:
Melchardt T.
[1
]
Weiss L.
[1
]
Greil R.
[1
]
Egle A.
[1
]
机构:
[1] Department of Internal Medicine III with Hematology, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Müllner Hauptstraße 48
关键词:
BEACOPPesc;
Brentuximab vedotin;
Hodgkin's lymphoma;
PET-CT;
D O I:
10.1007/s12254-013-0095-7
中图分类号:
学科分类号:
摘要:
Modern treatment strategies have resulted in an excellent overall survival in the majority of patients with Hodgkin's lymphoma. PET-stratification is used to guide treatment in patients with limited disease in clinical trials, but recent results indicate that combined treatment with chemotherapy and radiotherapy is still the standard of care. Prediction of treatment related mortality and new data about chemotherapy induced infertility will guide our decisions especially in patients with advanced disease and brentuximab vedotin is now an approved option in patients with relapsed or refractory disease. © Springer-Verlag Wien 2013.
引用
收藏
页码:193 / 196
页数:3
相关论文